202 related articles for article (PubMed ID: 29142038)
1. More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus.
Pakchotanon R; Gladman DD; Su J; Urowitz MB
J Rheumatol; 2018 Jan; 45(1):90-94. PubMed ID: 29142038
[TBL] [Abstract][Full Text] [Related]
2. Defining Low Disease Activity in Systemic Lupus Erythematosus.
Polachek A; Gladman DD; Su J; Urowitz MB
Arthritis Care Res (Hoboken); 2017 Jul; 69(7):997-1003. PubMed ID: 27696791
[TBL] [Abstract][Full Text] [Related]
3. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.
Akhavan PS; Su J; Lou W; Gladman DD; Urowitz MB; Fortin PR
J Rheumatol; 2013 Jun; 40(6):831-41. PubMed ID: 23588942
[TBL] [Abstract][Full Text] [Related]
4. Adherence to ophthalmologic monitoring for antimalarial toxicity in a lupus cohort.
Bernatsky S; Pineau C; Joseph L; Clarke A
J Rheumatol; 2003 Aug; 30(8):1756-60. PubMed ID: 12913931
[TBL] [Abstract][Full Text] [Related]
5. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
Ugarte-Gil MF; Hanly J; Urowitz M; Gordon C; Bae SC; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Clarke AE; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Ramsey-Goldman R; Manzi S; Jönsen A; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Lim S; Inanc M; Kalunian K; Jacobsen S; Peschken C; Kamen DL; Askanase A; Pons-Estel BA; Alarcón GS
Ann Rheum Dis; 2022 Nov; 81(11):1541-1548. PubMed ID: 35944946
[TBL] [Abstract][Full Text] [Related]
6. Smoking and Its Association With Morbidity in Systemic Lupus Erythematosus Evaluated by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index: Preliminary Data and Systematic Review.
Montes RA; Mocarzel LO; Lanzieri PG; Lopes LM; Carvalho A; Almeida JR
Arthritis Rheumatol; 2016 Feb; 68(2):441-8. PubMed ID: 26359794
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort.
Molad Y; Gorshtein A; Wysenbeek AJ; Guedj D; Majadla R; Weinberger A; Amit-Vazina M
Lupus; 2002; 11(6):356-61. PubMed ID: 12139373
[TBL] [Abstract][Full Text] [Related]
8. Age at diagnosis and health-related quality of life are associated with fatigue in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort.
Elera-Fitzcarrald C; Reátegui-Sokolova C; Gamboa-Cárdenas RV; Medina M; Zevallos F; Pimentel-Quiroz VR; Zeña-Huancas PA; Pastor-Asurza CA; Perich-Campos RA; Rodríguez-Bellido ZJ; Alarcón GS; Ugarte-Gil MF
Lupus; 2020 Oct; 29(12):1644-1649. PubMed ID: 32741305
[TBL] [Abstract][Full Text] [Related]
9. Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort.
Spinelli FR; Moscarelli E; Ceccarelli F; Miranda F; Perricone C; Truglia S; Garufi C; Massaro L; Morello F; Alessandri C; Valesini G; Conti F
Lupus; 2018 Sep; 27(10):1616-1623. PubMed ID: 29954281
[TBL] [Abstract][Full Text] [Related]
10. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort.
Petri M; Purvey S; Fang H; Magder LS
Arthritis Rheum; 2012 Dec; 64(12):4021-8. PubMed ID: 22932985
[TBL] [Abstract][Full Text] [Related]
11. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort.
Conti F; Ceccarelli F; Perricone C; Leccese I; Massaro L; Pacucci VA; Truglia S; Miranda F; Spinelli FR; Alessandri C; Valesini G
Lupus; 2016 Jun; 25(7):719-26. PubMed ID: 26821965
[TBL] [Abstract][Full Text] [Related]
12. Antimalarials in the treatment of systemic lupus erythematosus: a registry-based cohort study in Denmark.
Nørgaard JC; Stengaard-Pedersen K; Nørgaard M; de Thurah A
Lupus; 2015 Mar; 24(3):299-306. PubMed ID: 25318969
[TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus.
Parke A; West B
J Rheumatol; 1996 Oct; 23(10):1715-8. PubMed ID: 8895146
[TBL] [Abstract][Full Text] [Related]
14. Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus.
Stoll T; Stucki G; Malik J; Pyke S; Isenberg DA
J Rheumatol; 1997 Feb; 24(2):309-13. PubMed ID: 9034988
[TBL] [Abstract][Full Text] [Related]
15. Retinal Complications in Patients with Systemic Lupus Erythematosus Treated with Antimalarial Drugs.
Mukwikwi ER; Pineau CA; Vinet E; Clarke AE; Nashi E; Kalache F; Grenier LP; Bernatsky S
J Rheumatol; 2020 Apr; 47(4):553-556. PubMed ID: 31474597
[TBL] [Abstract][Full Text] [Related]
16. Antimalarial drug-induced aquagenic-type pruritus in patients with lupus.
Jiménez-Alonso J; Tercedor J; Jáimez L; García-Lora E
Arthritis Rheum; 1998 Apr; 41(4):744-5. PubMed ID: 9550488
[No Abstract] [Full Text] [Related]
17. Cutaneous lupus erythematosus: factors related to cutaneous activity and damage in a cohort of 260 patients from A Coruña, Spain.
Arévalo-Bermúdez MDP; Paradela S; Balboa-Barreiro V; Fonseca E
Lupus; 2020 Aug; 29(9):1021-1030. PubMed ID: 32539659
[TBL] [Abstract][Full Text] [Related]
18. Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort.
Pons-Estel GJ; Alarcón GS; Burgos PI; Hachuel L; Boggio G; Wojdyla D; Nieto R; Alvarellos A; Catoggio LJ; Guibert-Toledano M; Sarano J; Massardo L; Vásquez GM; Iglesias-Gamarra A; Lavras Costallat LT; Da Silva NA; Alfaro JL; Abadi I; Segami MI; Huerta G; Cardiel MH; Pons-Estel BA;
Lupus; 2013 Aug; 22(9):899-907. PubMed ID: 23857989
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Organ Damage Progression and Effect on Health-related Quality of Life in Systemic Lupus Erythematosus.
Legge A; Doucette S; Hanly JG
J Rheumatol; 2016 Jun; 43(6):1050-6. PubMed ID: 27084911
[TBL] [Abstract][Full Text] [Related]
20. Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre.
Hill DD; Eudy AM; Egger PJ; Fu Q; Petri MA
Lupus Sci Med; 2021 Apr; 8(1):. PubMed ID: 33832976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
